OBJECTIVES: While surgical ablation (SA) for persistent atrial fibrillation (AF) can reduce recurrence of AF, its impact on longitudinal survival and health-care costs remains controversial. This study defines the clinical outcomes and costs associated with SA in patients with prior AF undergoing coronary artery bypass grafting (CABG).
INTRODUCTION
Surgical ablation (SA) for atrial fibrillation (AF) has been shown to reduce AF recurrence in randomized controlled trials [1] [2] [3] and systematic reviews [4] [5] [6] . Most SAs are performed concomitant to other cardiac procedures. While the most commonly performed cardiac operation is coronary artery bypass grafting (CABG), the effects of SA on survival and health-care costs for patients with prior AF undergoing CABG are not well defined. The present study compares risk-adjusted clinical outcomes and inpatient care costs for patients with prior AF undergoing CABG with and without SA.
METHODS

Database and study population
The study cohort was derived from the 100% Medicare Standard Analytic File (SAF)-limited data set of inpatient admissions discharged in the 2013 calendar year. Patients were included in the study if they underwent CABG and were discharged between 1 January 2013 and 31 December 2013 and had persistent AF documented in the 12 months prior to CABG (defined as 2 inpatient or outpatient hospital admissions for AF, at least 7 days apart; Supplementary Material, Table S1 ). Patients were excluded if they were less than 18 years old; had a major cardiac procedure concomitant to CABG; or if inpatient and outpatient hospital admission claims for the 12 months prior to CABG revealed valvular AF [7] , rheumatic mitral stenosis, mitral valve repair, prosthetic valve replacement, previous CABG, previous endovascular or surgical AF ablation, previous left atrial appendage excision or exclusion, mechanical circulatory support or heart transplantation (Supplementary Material, Table S2 ). In addition, patients were excluded if they were not continuously eligible for Medicare Part A and B benefits during all of 2012-2014, had insufficient demographic claims data, if no corresponding record was available in the Medicare denominator file used to identify patient deaths or if CABG cost was greater than 3 SDs from the mean. Only the first CABG admission was included, and the unit of analysis was the individual discharge. The final study cohort consisted of 3745 patients (Fig. 1) .
Comorbidities
Clinical diagnoses and procedures occurring in the year prior to and the year after CABG were identified in the 100% Medicare SAF of inpatient and outpatient hospital admissions discharged in the 2012-2014 calendar years, respectively (see Supplementary Material, Table S3 ). Comorbidities and procedural characteristics utilized in the Society of Thoracic Surgeons (STS) risk model for CABG [8] were collected from the claims for each patient when corresponding fields were present in the Medicare SAF (Supplementary Material, Table S3 ). In addition, comorbidities associated with mortality and resource utilization and validated for risk adjustment of administrative data [9, 10] were collected from each patient claim. Both the CHA 2 DS 2 -VASc [11] score and the HAS-BLED score [12] were calculated for each patient (Supplementary Methods and Supplementary  Material, Table S4 ).
End-points
Perioperative clinical end-points were operative mortality, defined as any death within 30 days of CABG or during the CABG admission, whichever was longer; postoperative stroke, defined as any new ischaemic stroke, intracranial haemorrhage or subarachnoid haemorrhage during the CABG admission; perioperative renal failure, defined as any new end-stage renal disease or renal dialysis; and perioperative pericardial complications, defined as haemopericardium or pericardiocentesis (Supplementary Material, Table S5 ).
Long-term follow-up end-points were recurrent atrial tachyarrhythmia, defined as an inpatient or outpatient admission for AF, atrial flutter or other atrial tachycardia; AF-related interventions, defined as SA, percutaneous atrial ablation or left atrial exclusion or excision; stroke, defined as a new ischaemic stroke or intracranial haemorrhage/subarachnoid haemorrhage; and implantation of a cardiovascular implantable electronic device (CIED), defined as a single-/dual-chamber pacemaker or implantable cardioverter/defibrillator or biventricular pacemaker, with or without a defibrillator (Supplementary Material, Table S5 ).
Resource utilization end-points were cost and length of stay of the CABG admission and inpatient readmissions in the first year following CABG (Supplementary Methods). Deaths following discharge were identified in the Medicare denominator file.
Statistical analysis
Continuous variables were presented as mean ± standard deviation or 95% confidence intervals and were compared with Student's t-test. Categorical variables were provided as counts with percentages and compared with a v 2 test. Kaplan-Meier survival estimates were compared using a log-rank test. All tests were 2-tailed, with a significance threshold of 0.05. Reporting patient counts of less than 11 was not permitted by Centers for Medicare and Medicaid Service (CMS) privacy regulations. Calculations were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
Unadjusted survival following CABG was estimated using product-limit (Kaplan-Meier) analysis with strata for AF, with and without SA. A Cox proportional hazard (PH) specification was initially used to estimate the risk-adjusted hazard ratio (HR) for death following CABG, for patients with and without SA. Using this approach, we found the PH assumption was not satisfied throughout the first postoperative year for several covariates. Therefore, a piecewise Cox PH model for mortality was employed, similar to others [13] [14] [15] [16] . The first year following CABG was divided into 2 intervals, 0-90 days (early) and 91-364 days (late), and data were fit to separate Cox PH models for each interval. Because interaction terms did not substantially improve the model fit of either specification, they were not included (see Supplementary Methods, for additional details of the PH model).
Regression specifications were used to estimate risk-adjusted odds ratios for the other categorical end-points and risk ratios for the cost and inpatient length of stay (Supplementary Methods). The specifications for stroke contained a term for the CHA 2 DS 2 -VASc score [11] , and the specification for bleeding contained a term for the HAS-BLED score [12] .
Ethical considerations
The Sterling Institutional Review Board (Atlanta, GA, USA) determined the study was exempt from institutional review board review, pursuant to the terms of the US Department of Health and Human Services' Policy for Protection of Human Research Subjects (45 C.F.R. section 46.101 (b)).
RESULTS
The study cohort of 3745 patients with prior AF who underwent CABG had an average age of 74 ± 7 years, 26% were women, 7% were non-White and 12% were eligible for Medicaid (Table 1) . Hypertension was present in 96%, 50% had diabetes, 32% had chronic lung disease, 27% had peripheral arterial disease, 24% had cerebrovascular disease, 35% had heart failure in the 2 weeks prior to admission, 21% were admitted emergently and 15% had an myocardial infarction in the year prior to CABG. At least 1 arterial coronary graft was used in 93% of patients, and 95% of patients had at least 1 non-arterial graft (Table 2) .
Concomitant SA was performed in 626 patients (17%) (Fig. 1 ), who were more often male, and more often White, than patients without SA (Table 1) . Preoperative characteristics favoured patients with SA-they had less chronic lung disease, renal failure, peripheral arterial disease, prior percutaneous coronary intervention, heart failure in the 2 weeks prior to admission, emergent presentation, intra-aortic balloon pump use the day of or after CABG and had lower CHA 2 DS 2 -VASc scores, compared with patients without SA (Table 2 and Supplementary Material, Table S6 ).
Operative mortality and postoperative complication rates did not differ significantly between patients with and without SA, before or after risk adjustment (Table 3) , although the specifications used to risk adjust the rate of postoperative stroke and renal failure were not robust (Supplementary Material, Table S7 ).
One year following CABG, only the associations between SA and CIED implantation (odds ratio = 1.20; P = 0.01) and between SA and admission for atrial flutter recurrence (odds ratio = 1.30; P = 0.02) were significant, although the specification used to risk adjust AF recurrence was not robust (Supplementary Material,  Tables S3 and S7) .
One year following CABG, patients with SA had significantly lower unadjusted mortality than patients without SA (9.7% vs 13.9%; P < 0.007) (Fig. 2) . After risk adjustment, survival in the early postoperative period (0-90 days) was similar with and without SA [HR = 1.03 95% confidence interval (0.74-1.43); P = 0.86]. However, patients with SA had significantly better risk-adjusted survival in the late postoperative period (91-364 days) than patients without SA [HR = 0.58 95% confidence interval (0.35-0.95); P = 0.03] ( Table 4) .
Prior to risk adjustment, patients with SA had elevated costs of the index CABG with a mean-unadjusted incremental cost of US$2225. However, CABG-SA had lower readmission costs and similar total inpatient admission costs during the first year (combined CABG admission and all readmissions) than patients without SA (Table 5) . After risk adjustment, the index CABG admission costs with SA were 11% higher (P < 0.01) and total inpatient admission costs during the first year were 6% higher (P = 0.02), compared with patients without SA, although the specifications used to risk adjust the CABG admission and total costs were not robust (Table 5 and Supplementary Material, Table S8 ). 
DISCUSSION
The important findings of this study were that for patients with AF who underwent CABG, no significant difference in riskadjusted rates of perioperative death and complications were observed with or without SA. The adjusted cost of the CABG admission was 11% higher with SA. However, the adjusted risk of death in the late postoperative period (91-364 days) was reduced by half following SA, compared to without SA. In the present study, comorbidities generally were similar to patients in the STS database who underwent CABG from 2002 to 2007 [13] . Notable differences in the current study were that AF was present in all patients (100% vs 7%), more were men (74% vs 68%), more had heart failure (35% vs 15%), diabetes (50% vs 36%), hypertension (96% vs 82%) and chronic lung disease (32% vs 21%), while fewer had prior percutaneous coronary intervention (5% vs 20%), prior myocardial infarction (15% vs 43%), mitral regurgitation (6% vs 14%) and intra-aortic balloon pump prior to CABG (2% vs 7%).
The Medicare administrative database does not contain procedural details, so the ablation lesion set and energy source are not available. Some insight into these details is provided by a recent study of the STS database patients who underwent CABG with SA over this same period [17] . In that study, 58% of SA patients had left atrial-only lesion sets, 56% of procedures were epicardial, radiofrequency was the energy source in 43%, the left atrial appendage was obliterated in 89% and at discharge, 58% were on warfarin and 53% on antiarrhythmics. Thus, it is likely that most CABG patients in the current study received radiofrequency pulmonary vein isolation, a procedure that has been associated with sinus conversion rates of 60-80% [18, 19] . It is also possible that additional surgical experience, or routine performance of more complete lesion sets, could further improve results [4] .
Several risk-adjusted cohort studies in patients with and without valve disease suggest long-term survival may be increased in patients with preoperative AF who maintain sinus rhythm following SA [20] [21] [22] . While randomized controlled trials [1] [2] [3] and large systematic reviews [4] [5] [6] demonstrate SA reduces recurrence of AF, definition of a mortality benefit has been more difficult. This finding could be related to limited sample size, short duration of follow-up and/or less severe underlying cardiac disease in some randomized controlled trials. Another factor may be that energy sources and lesion sets have evolved significantly, and current techniques are more effective. The merits of SA and its impact on outcome have been summarized by the STS in recent guidelines [23] , which make SA for AF at the time of CABG a Class I recommendation with level of evidence B (non-randomized). The current study corroborates these important concepts and adds information on the positive impact of SA on longitudinal outcome and cost.
In the current study, patients with SA had an adjusted risk of CIED utilization that was about 20% higher than patients without SA. Certainly, some of the devices were required for dysrhythmias caused or unmasked by SA. However, this finding also may reflect more aggressive efforts to maintain sinus rhythm electrically or pharmacologically, requiring CIED implantation. While it is not possible to determine the indication for CIED implantation in each patient from the Medicare database used in this study, it is an important topic for future research.
Patients with SA had risk-adjusted CABG admission costs that were about 11% higher than patients who did not. This unadjusted increment averaged US$2225 and likely reflected the index cost of the SA instrumentation. Because of fewer readmissions, risk-adjusted total inpatient costs at 1 year fell to 6% higher in patients with SA. A longer term assessment of inpatient costs in the current patient series seems indicated.
Limitations
This study has several limitations. First, these data were collected from the Medicare SAF, which is a claims-based database. While this database is designed to accurately capture the occurrence, duration and cost of inpatient and outpatient hospital admissions, it is not optimized to capture comprehensive clinical details. Second, because inpatient physicians' fees and required outpatient care are not captured, it may underestimate total costs associated with CABG, with or without SA. Patients following CABG with a cost greater than 3 SD from the mean were excluded from this study and may be a source of bias. Finally, cost data are based on calculations made from charges and costto-charge ratios rather than direct cost data. Despite these limitations, the results from this large observational study provide useful insights into the clinical outcomes and costs of SA with CABG in Medicare beneficiaries.
CONCLUSION
In summary, in this analysis of US Medicare beneficiaries with AF who underwent CABG with SA, early postoperative risk was not increased compared with those without SA, but late survival (91-364 days) was significantly augmented. These findings suggest important longitudinal survival benefits associated with SA in patient with AF who undergo CABG. Despite an incremental procedural cost at the time of CABG, these data also suggest that SA may be a cost-effective strategy to improve clinical outcomes in CABG patients with AF.
